Total Payments
$268,275
2024 Payments
$30,489
Companies
49
Transactions
874
Medicare Patients
836
Medicare Billing
$173,273
Payment Breakdown by Category
Other$190,183 (70.9%)
Consulting$35,060 (13.1%)
Food & Beverage$21,665 (8.1%)
Travel$20,366 (7.6%)
Education$1,001 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $157,690 | 74 | 58.8% |
| Consulting Fee | $35,060 | 14 | 13.1% |
| Honoraria | $25,293 | 9 | 9.4% |
| Food and Beverage | $21,665 | 689 | 8.1% |
| Travel and Lodging | $20,366 | 70 | 7.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,200 | 3 | 2.7% |
| Education | $1,001 | 15 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $108,159 | 170 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $29,294 | 64 | $0 (2024) |
| Merck Sharp & Dohme LLC | $27,775 | 45 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $24,590 | 33 | $0 (2022) |
| Exelixis Inc. | $14,577 | 41 | $0 (2024) |
| Sirtex Medical Inc | $11,117 | 22 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9,339 | 16 | $0 (2019) |
| Millennium Pharmaceuticals, Inc. | $9,024 | 7 | $0 (2017) |
| Eisai Inc. | $6,661 | 26 | $0 (2024) |
| Daiichi Sankyo Inc. | $5,634 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,489 | 163 | AstraZeneca Pharmaceuticals LP ($12,548) |
| 2023 | $25,264 | 164 | AstraZeneca Pharmaceuticals LP ($21,869) |
| 2022 | $36,080 | 84 | AstraZeneca Pharmaceuticals LP ($20,699) |
| 2021 | $26,432 | 61 | AstraZeneca Pharmaceuticals LP ($14,493) |
| 2020 | $21,415 | 44 | AstraZeneca Pharmaceuticals LP ($10,732) |
| 2019 | $39,641 | 118 | Takeda Pharmaceuticals U.S.A., Inc. ($16,669) |
| 2018 | $40,265 | 144 | AstraZeneca Pharmaceuticals LP ($15,810) |
| 2017 | $48,689 | 96 | Merck Sharp & Dohme Corporation ($27,059) |
All Payment Transactions
874 individual payment records from CMS Open Payments — Page 3 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/19/2024 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: BioOncology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $23.00 | General |
| 08/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: ONCOLOGY | ||||||
| 08/07/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/07/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $29.94 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: BioOncology | ||||||
| 07/31/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $28.67 | General |
| 07/30/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $26.22 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Genentech USA, Inc. | Hemlibra (Biological) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Hematology | ||||||
| 07/26/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: ONCOLOGY | ||||||
| 07/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $3.99 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/22/2024 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $32.19 | General |
| Category: BioOncology | ||||||
| 07/15/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: BioOncology | ||||||
| 07/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Oncology | ||||||
| 07/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.56 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $4.51 | General |
| Category: Oncology | ||||||
| 07/08/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: BioOncology | ||||||
| 07/03/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: Oncology | ||||||
| 07/01/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 186 | 381 | $113,462 | $31,371 |
| 2022 | 5 | 181 | 489 | $152,975 | $47,435 |
| 2021 | 9 | 262 | 527 | $184,996 | $54,779 |
| 2020 | 7 | 207 | 523 | $169,358 | $39,688 |
Total Patients
836
Total Services
1,920
Medicare Billing
$173,273
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 215 | $64,130 | $17,156 | 26.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 51 | $21,630 | $5,833 | 27.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 32 | $12,012 | $3,478 | 29.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 38 | $8,340 | $2,746 | 32.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 31 | $6,370 | $1,870 | 29.4% |
| 85060 | Blood smear interpretation by physician with written report | Facility | 2023 | 13 | 14 | $980.00 | $288.21 | 29.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 84 | 351 | $101,450 | $30,793 | 30.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 56 | $24,085 | $7,599 | 31.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 24 | 25 | $9,750 | $3,235 | 33.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $9,690 | $3,179 | 32.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 40 | $8,000 | $2,629 | 32.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 78 | 267 | $85,173 | $23,136 | 27.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 40 | 95 | $40,565 | $12,830 | 31.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 28 | 30 | $17,700 | $5,712 | 32.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 21 | 21 | $12,768 | $3,786 | 29.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 23 | 23 | $9,177 | $2,954 | 32.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 41 | $8,979 | $2,443 | 27.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 18 | $5,436 | $1,766 | 32.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 18 | $3,798 | $1,231 | 32.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 14 | 14 | $1,400 | $921.34 | 65.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 69 | 309 | $98,571 | $22,374 | 22.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 31 | 74 | $31,598 | $7,406 | 23.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $9,440 | $2,928 | 31.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 15 | 15 | $9,120 | $2,414 | 26.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 38 | 49 | $10,731 | $2,232 | 20.8% |
About Dr. Yiwu Huang, MD
Dr. Yiwu Huang, MD is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780798462.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yiwu Huang, MD has received a total of $268,275 in payments from pharmaceutical and medical device companies, with $30,489 received in 2024. These payments were reported across 874 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($157,690).
As a Medicare-enrolled provider, Huang has provided services to 836 Medicare beneficiaries, totaling 1,920 services with total Medicare billing of $173,273. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 08/18/2006
- Last Updated 08/23/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780798462
Products in Payments
- IMFINZI (Biological) $49,656
- NINLARO (Drug) $37,727
- IMFINZI (Drug) $28,330
- TAGRISSO (Drug) $28,137
- Tavalisse (Drug) $24,590
- SIR-Spheres Microspheres (Device) $11,117
- CABOMETYX (Drug) $10,856
- Lenvima (Drug) $6,645
- GILOTRIF (Drug) $5,854
- Enhertu (Drug) $5,599
- Cabometyx (Drug) $3,671
- VYXEOS (Drug) $2,823
- PDR001 (Drug) $2,748
- LOQTORZI (Biological) $2,264
- KEYTRUDA (Biological) $905.18
- OPDIVO (Biological) $594.68
- BRUKINSA (Drug) $525.00
- Revlimid (Drug) $469.75
- Venclexta (Biological) $426.21
- KISQALI (Drug) $401.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Perry Cook, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Hematology & Oncology $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Hematology & Oncology $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Hematology & Oncology $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699
Hematology & Oncology $48,699
Yan Pronin, P.a, P.A
Hematology & Oncology — Payments: $47,040
Hematology & Oncology $47,040